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Background: Advanced glycation end products (AGEs), inflammatory-associated macrophage migration and
accumulation are crucial for initiation and progression of diabetic vascular complication. Enzymatic activity of
heparanase (HPA) is implicated strongly in dissemination of metastatic tumor cells and cells of the immune system.
In addition, HPA enhances the phosphorylation of selected signaling molecules including AKT pathway
independent of enzymatic activity. However, virtually nothing is presently known the role of HPA during
macrophage migration exposed to AGEs involving signal pathway.
Methods: These studies were carried out in Ana-1 macrophages. Macrophage viability was measured by MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays. HPA and AKT protein expression in
macrophages are analysed by Western blotting and HPA mRNA expression by real time quantitative RT-PCR.
Release of HPA was determined by ELISA. Macrophage migration was assessed by Transwell assays.
Results: HPA protein and mRNA were found to be increased significantly in AGEs-treated macrophages.
Pretreatment with anti-HPA antibody which recognizes the nonenzymatic terminal of HPA prevented AGEs-induced
AKT phosphorylation and macrophage migration. LY294002 (PI3k/AKT inhibitor) inhibited AGEs-induced
macrophage migration. Furthermore, pretreatment with anti-receptor for advanced glycation end products (RAGE)
antibody attenuated AGEs-induced HPA expression, AKT phosphorylation and macrophage migration.
Conclusions: These data indicate that AGEs-induced macrophage migration is dependent on HPA involving
RAGE-HPA-PI3K/AKT pathway. The nonenzymatic activity of HPA may play a key role in AGEs-induced macrophage
migration associated with inflammation in diabetic vascular complication.
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Advanced glycation end products (AGEs), final products
of the non-enzymatic reaction between reducing sugars
and amino groups in proteins, lipids and nucleic acids,
promotes inflammation to accelerate the progression of
vascular disease in patients with diabetes as well as other
mechanisms [1]. Inflammatory-associated macrophage
migration and accumulation in inflamed tissue sites are
implicated in the major pathogenic process of vascular* Correspondence: yonggu@vip.163.com
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reproduction in any medium, provided the orcomplications in diabetes [2-4]. Although the accumula-
tion of advanced glycation end products (AGEs), chronic
inflammation-associated macrophage migration and ac-
cumulation play critical roles in vascular complication
development of diabetes [5-7], knowledge regarding the
relationship between AGEs and macrophage migration
through extracellular matrix is still unclear.
Heparanase (HPA), an endo-β-glucuronidase, is strongly
implicated in cell dissemination associated with tumor
metastasis and inflammation. It can cleave heparan sulfate
side chains of heparan sulfate proteoglycans to participate
in extracellular matrix remodeling and regulate the release
of many heparan sulfate-bonded molecules include
inflammatory cytokines [8-10]. Moreover, HPA has non-. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cascades and selected protein kinase activation associated
with cell migration [11,12]. Evidences have shown that
over-expressed HPA in most human cancers allow them
to penetrate the endothelial cell layer and basement mem-
brane to invade target organs [13,14]. Increased expression
of HPA is essential for the development of microvascular
complication such as diabetic nephropathy in mice and
associated with inflammation in human atherosclerosis
[15-17].
Recently, several reports have indicated that AGEs
increased HPA expression to facilitate migration of cell
associated with inflammation in adult tubular and endo-
thelial cells [18-20]. However, it is unknown whether
macrophage migration is induced by AGEs in HPA-
dependent manner.
Given the crucial role of AGEs and macrophage mi-
gration in the progression of diabetic complications, we
thoroughly investigated the effect of AGEs on macro-
phage migration via HPA independent of enzyme acti-
vity. In particular, we analyzed: the effects of AGEs on
the mRNA, protein and secretion of HPA; the signaling
pathways involved; the effect of an altered HPA expres-
sion on macrophage migration and the mechanisms.
Materials and methods
Materials
RPMI 1640 and fetal bovine serum (FBS) were from
GibcoTM Invitrogen Corporation (Grand Island, NY).
Advanced glycation end products (Glycated bovine serum
albumin) was from Shanghai Yixin Bio-Technology Co.
Ltd (Shanghai, China). RevertAid First Strand cDNA
Synthesis Kit was from Fermentas International Inc
(Graiciuno, Vilnius, Lithuania). Real time PCR Master Mix
was from Delaware Biotechnology Institute (Newark,DE).
SuperECL Plus and LY 294002 were from Beytime Insti-
tute of Biotechnology (Haimeng, China). ELISA kit for
mouse HPA was from Glory Science Co,Ltd (Hangzhou,
China). Rabbit anti-mouse HPA, RAGE, AKT antibody
and peroxidase-labeled goat anti-rabbit second antibody
were from Wuhan Boster Bio-engineering Limited Com-
pany (Wuhan, China). Rabbit anti-mouse GAPDH
antibody was from Santa Cruz Biotechnology Inc (Santa
Cruz, CA); Rabbit anti-mouse phospho-AKT antibody was
from Cell Signaling Technology (Boston, MA). MTT was
from Sigma-Aldrich (Shanghai, China). Falcon™ cell
culture insert system was from Becton Dickinson and
Company (Franklin Lakes, NJ).
Cell culture
Ana-1 mouse macrophage cell line was obtained from the
cell bank of Shanghai Institutes for Biological Sciences,
Chinese Academy of Sciences (Shanghai, China). Cells
were maintained in RPMI 1640 medium supplementedwith 10% fetal bovine serum and 100 units/ml penicillin
and 100 μg/ml streptomycin and were incubated at 37°C
in 5% CO2 humidified air. Spent medium was replaced
every 2–3 days. Cells were grown to 80% confluence and
then serum-starved for 16 hours before use.
MTT assay
In order to determine the effects and mechanism of
AGEs on HPA in macrophages, we performed assays to
determine the concentrate of AGEs, LY294002 (PI3k/
Akt inhibitor), anti-HPA and RAGE antibody which
didn’t change the viability of macrophages significantly.
100 μl macrophages were seeded at a density of 5 × 104
cells/ml and incubated with AGEs, LY294002, anti-HPA
and RAGE antibody at the indicated concentration in
96-well plates. After 24 h incubation, 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
solution was added to each well for 4 hours. Finally, the
blue salt in each well was dissolved and the plates were
read by using a microplate reader with RPMI 1640 as
blank and cell culture medium as control. The results of
cell viability determined 100 mg/L AGEs, 15 μM
LY294002, 10 μg/ml anti-RAGE and 10 μg/ml anti-HPA
antibody in the following experiments (The choice of
dosage is showed in results and discussion).
Treatments with cells
First, we evaluate the role of RAGE, HPA, AKT in
AGEs-induced macrophage migration. Cells were treated
with AGEs (100 mg/L), and LY294002 (pre-treated with
15 μM LY294002), and anti-RAGE or HPA antibody
(pre-treated with 10 μg/ml anti-RAGE or HPA antibody)
for 24 h. Subsequently, cells were treated with AGEs
(100 mg/L), and anti-RAGE antibody (pre-treated with
10 μg/ml anti-RAGE antibody) for 24 h and analyzed by
RT-PCR, Western blot and ELISA assay to examine
effects of AGEs on HPA expression and the role of re-
ceptor for advanced glycaiton end products (RAGE) in
AGEs-induced HPA expression. Finally, we treated cells
with AGEs (100 mg/L), and anti-RAGE or HPA antibody
(pre-treated with 10 μg/ml anti-RAGE or HPA antibody)
for 24 h, and harvested for Western blot analysis to
assess of the role of HPA and RAGE in AGEs-induced
activation of AKT.
Migration assay
Macrophages used for seeding transwell inserts were
harvested from the plate by incubating as above and
plated into transwell inserts with 8 μm pores, which were
coated with a thin layer of Matrigel and placed in a 6-well
plate. 2% FBS were added to the lower chamber. Plates
were incubated for 6 h at 37°C. Cells remaining on the
upper membrane surface were removed with a cotton
swab. Upper wells were placed into 4% paraformaldehyde
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membrane. Migrated cells were stained with hematoxylin
and counted (6 random fields per slide) in ten 40× fields.
ELISA for HPA
The Ana-1 macrophages were plated at 5 × 105 cells/well
in 24 well plates overnight. Macrophages were cultured
separately with 100 mg/L AGEs, and anti-RAGE anti-
body (pre-treated with 10 μg/ml anti-RAGE antibody)
for 24 h. The levels of HPA in culture supernatants were
determined using commercially available enzyme linked
immunosorbent assay (ELISA) kits according to the
manufacturer’s instructions. Briefly, 10 μl supernatant
and 40 μl sample diluent was added to sample well,
followed by the addition of 100 μl HRP-conjugate re-
agent to each well and incubated for 60 minutes at 37°C.
The reaction was visualized by the addition of 50 μl
chromogen solution A and 50 μl chromogen solution B
for 15 min at 37°C. The reaction was stopped with 50 μl
stop solution and absorbance at 450 nm was measured
using ELISA plate reader within 15 min. The level of
HPA was quantified by a standard curve established by a
serial dilution of standard concentration.Detection of mRNAs by real time quantitative RT-PCR
RNA from Ana-1 macrophages was isolated using
TRIZOL reagent following the manufacturer’s instruc-
tions. Isolated RNA was reversed transcribed into comple-
mentary DNA using RevertAid First Strand cDNA
Synthesis Kit according to the protocol by the manufac-
turer. To determine the fold-changes in the expression of
HPA gene, real-time PCR was performed using the first
strand cDNA, the forward and reverse primers (forward:
GAACCTCCATAATGTCACCAAGC, resverse: GTCTG
CTCATCCACCATCTTCAG), and Bestar™ Taqman Real
time PCR master mix. Thermocycling conditions for
SYBR Green consisted of a denaturation step for 2 min at
95°C followed by 35 cycles of 95°C for 15 s, 59°C for 30 s
and 72°C 15 s. Data analysis was performed using standard
curve method and ΔΔCt method. The mount of HPA was
determined and normalized by the amount of GAPDH
cDNA.
Western blot analysis
The cells were lysed with dissociation solution containing
phosphatase, protease inhibitors and PMSF. Protein
extracted from macrophages was electrophoresed on
SDS-polyacrylamide gels (10%) and Western blotted.
Proteins were transblotted onto nitrocellulose membrane.
Membranes with the transferred proteins were blocked for
1 hour with 5% (w/v) skim milk powder diluted in
PBS and then incubated with anti-HPA, AKT or
phosphorylated (p)-AKT antibodies (1:1000 dilution)respectively at 4°C overnight. The membranes were
incubated with a peroxidase-conjugated secondary anti-
body respectively and visualized by a supper enhanced
chemiluminesence detection system. Densitometric ana-
lysis was performed by normalizing band density to that
for GAPDH.
Statistical analysis
The data were expressed as mean ± SEM. Statistical ana-
lysis was performed by SPSS software using one-way
analysis of variance (ANOVA). A value of P < 0.05 was
considered statistically significant.Results
Cell viability
Incubation of Ana-1 macrophages with AGEs (25–
400 mg/L) for 3,6,12 and 24 h led to the significant dose-
dependent reduction in the viability of cells compared
with controls. AGEs didn’t change significantly the viabi-
lity of Ana-1 macrophages within 25-100 mg/L AGEs con-
centration range for 3,6,12 and 24 h incubation
(Figure 1A). Therefore, we chose the max dosage of AGEs
at 100 mg/L, which didn’t change the viability significantly
in Ana-1 macrophages within 24 h incubation, to finish
the following experiments involving the mechanism.
Subsequently, macrophages were pre-treated with
LY294002 (7.5-120 μM) for 1 h before culture with
100 mg/L AGEs except control group. The treatment of
macrophages with LY294002 (7.5-15 μM) and 100 mg/L
AGEs within 24 h culture didn’t affect cell viability sig-
nificantly. Exposure to LY294002 (30–120 μM) and
100 mg/L AGEs for 3, 6, 12, 24 h decreased macrophage
viability significantly (Figure 1B). We chose the max
dosage of LY294002 at15 μM and 100 mg/L AGEs for
24 h incubation, which didn’t change the viability signifi-
cantly in Ana-1 macrophages, to finish the following
experiments.
In addition, the pre-treatment with 10 μg/ml anti-
RAGE or 10 μg/ml anti-HPA antibody in 100 mg/L
AGEs-induced macrophages for 24 h culture didn’t
change the cell viability significantly (Figure 1C).HPA play a key role in the AGEs-induced macrophage
migration involving RAGE and PI3K/AKT pathway
To investigate the effect of AGEs on macrophage migra-
tion, we used the cell culture insert system and found
more macrophage migration after co-culture of AGEs
with macrophages for 24 h. Meanwhile, we performed
the changes of the AGEs-induced macrophage migration
using anti-HPA antibody which recognizes the COOH-
terminal domain, nonenzymatic terminal, to determine
the signaling role of HPA in AGEs-induced macrophages
Figure 1 Viability analysis of Ana-1 macrophages after treatment with AGEs, LY294002, anti-RAGE or HPA antibody. Cell viability assay is
performed using MTT assay. A, Cells (5 × 104) were treated with AGEs (0, 25, 50, 100, 200 and 400 mg/L) for 3, 6, 12, 24 h. B, Cells (5 × 104) were
pretreated with LY294002 (7.5-120 μM) for 1 h before culture with 100 mg/L AGEs for 3, 6, 12, 24 h. C, Cells (5 × 104) were pretreated with
anti-RAGE or HPA antibody for 1 h before culture with 100 mg/L AGEs for 3, 6, 12, 24 h. The results represent the mean of six culture wells
(mean ± SEM). *p < 0.05, as compared to the control group. All of the experiments were performed independently in triplicate.
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phage migration was reduced after pretreatment with
anti-HPA antibody for 1 h. In addition, pretreatment
with anti-RAGE antibody or LY294002 for 1 h decreased
the AGEs-induced macrophages migration significantly
(Figure 2). The results explore that HPA mediates
AGEs-induced macrophage migration and may involve
RAGE and AKT pathway.AGEs changes HPA mRNA, protein expression and
secretion via RAGE in macrophages
To test the possible effect and mechanism of AGEs treat-
ment on HPA expression, Ana-1 macrophages were
incubated for 24 h in the presence of 100 mg/L AGEs with
or without the pretreatment of 10 μg/ml anti-RAGE anti-
body for 1 h. Using RT-PCR and ELISA assays, we show
that AGEs promoted the levels of mRNA and secretion
significantly in macrophages. Pretreatment with anti-
RAGE antibody significantly inhibited HPA secretion
and mRNA production in AGEs-induced macrophages
(Figure 3A and 3B).
Furthermore, the HPA latent form (65 kDa) and active
form (50 kDa) were identified using an antibody against
the C-terminus domain of HPA protein. We show that
untreated cells primarily expressed the 65 kDa latent form.
Both of 65 kDa and 50 kDa forms were increased signifi-
cantly and the 50 kDa actived form was more strongly
induced as compared with the 65 kDa latent form in
AGEs-induced macrophages. Pretreatment with anti-
RAGE antibody attenuated AGEs-induced 50 kDa actived
and 65 kDa latent forms in macrophages (Figure 3C).Figure 2 HPA, RAGE and PI3K/AKT pathway correlate with AGEs-indu
with or without pre-treatment with LY294002, anti-HPA or RAGE antibody
normalized to the number of macrophages that migrated in control group
*p < 0.05 compared to control and #p <0.05 compared to AGEs. All of thePhosphorylation of AKT are increased in AGEs-stimulated
macrophages via HPA involving RAGE
We examine the expression of AKT protein in
macrophages to explain the role of PI3K/AKT signaling
pathway in AGEs-induced macrophage migration via
HPA. We found that the phosphorylation of AKT was
increased significantly at 24 h of stimulation with AGEs
in macrophages. The expression of AKT phosphoryl-
ation could be inhibited by the pretreatment of an
antibody recognizing the COOH-terminal domain of
HPA protein or anti-RAGE antibody in AGEs-induced
macrophages. Furthermore, we didn’t find the changes
of total AKT protein in macrophages with different
treatment (Figure 4).
Discussion
Cardiovascular complications are the leading cause of
death in patients in diabetic patients [21,22]. The
current study provides evidence to support that excess
accumulation of advanced glycation end products
(AGEs) and inflammation is emerging as important
mechanism for micro- and macrovascular complication
of diabetes [23,24]. Monocytes transmigrate into the
subendothelial space and differentiate into macrophages,
which migrate, infiltrate and accumulate in the vascular
tissues, involving in diabetic vascular complications.
Clinical study has also observed significant increase of
AGEs accumulation in diabetic vascular tissues [25],
which may induce macrophage migration across an
endothelial cell monolayer [26].
Heparanase (HPA), a mammalian endo-beta-D-glu-
curoxnidase, has previously been shown to be a keyced macrophage migration. Cells were cultured with AGEs for 24 h
for 1 h. The migration was measured by transwell assays. Results were
. The results represent the mean of six culture wells (mean ± SEM).
experiments were performed independently in triplicate.
Figure 3 AGEs up-regulates HPA mRNA, protein expression and secretion in macrophages via RAGE. Cells were cultured with AGEs for
24 h with or without pre-treatment with antibody against RAGE for 1 h. A, The levels of HPA mRNA were assessed with real time quantitative
RT-PCR. B, The secretion of HPA in supernatant was measured by enzyme-linked immunosorbent assay (ELISA). C, The expression of HPA protein
in macrophages was determined by Western blotting. The results represent the mean of six culture wells (mean ± SEM). *p < 0.05 compared to
control and #p <0.05 compared to AGEs. All of the experiments were performed independently in triplicate.
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cells and cells of the immune system [27-29]. Recently,
evidences show that HPA enhances the phosphorylation
of selected signaling molecules, in a manner that is
mediated by its C-terminal domain but not enzymaticFigure 4 The expression of AKT protein in AGEs-induced macrophage
RAGE or HPA for 1 h before exposed to AGEs for 24 h. AKT and p-AKT prot
and p-AKT antibody. The results represent the mean of six culture wells (m
AGEs. All of the experiments were performed independently in triplicate.activity [12,30]. In the study, we have characterized the
role and mechanism of HPA in AGEs-induced macro-
phage migration independent of enzymatic activity.
With the MTT assay we observed the dose-dependent
reduction of viability in macrophages treated by AGEs.s. Cells were cultured with AGEs or pretreated with antibody against
ein expression is determined by Western blot analysis using anti-AKT
ean ± SEM). *P < 0.05 compared to control and #P <0.05 compared to
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AGEs in macrophages. AGEs treatment at 25, 50 and
100 mg/L for 3,6,12 and 24 h incubation didn’t result in
a significant loss of viability in macrophages compared
with controls (0 mg/L) (Figure 1A). We then used
100 mg/L AGEs, a max dosage which didn’t changed the
viability significantly within studied AGEs concentration
range at 24 h culture, for further studies on the role of
HPA in macrophages.
Moreover, pretreatment with LY294002 (7.5-15 μM),
anti-RAGE or HPA antibody (10 μg/ml) for 1 h before
culture with 100 mg/L AGEs for 3,6,12 and 24 h incuba-
tion didn’t result in a significant loss of viability in
macrophages compared with controls (Figure 1B). We
then used preincubation of 15 μM LY294002, 10 μg/ml
anti-RAGE or HPA antibody, the dosage which didn’t
changed the viability significantly within the studied
concentration range at 24 h culture, for further studies
in 100 mg/L AGEs-induced macrophages.
Evidences have shown that HPA play a role in signaling
pathway [31]. C-terminus domain mediates nonenzymatic
functions of HPA, facilitating the phosphorylation of
phosphatidylinositol 3-kinase/protein kinase B (PI3K/
AKT), in an enzymatic activity-independent manner in pi-
tuitary tumor and proximal tubular [32,33]. Recent studies
show that AKT (protein kinase B), a serine/threonine pro-
tein kinase, regulates monocyte/macrophage migration.
Inhibition of AKT pathways decreased macrophage migra-
tion while mammalian cell migration can be promoted by
enhancing AKT signaling [34-36].
In agreement with previous study [26,37], we have shown
that AGEs induced macrophage migration significantly.
However, more importantly, we have shown that pretreat-
ment of anti-HPA antibody, which bind to the C-terminus
domain of HPA specially, inhibited the macrophage
migration significantly (Figure 2). This demonstrates that
C-terminus domain of HPA mediates AGEs-induced
macrophage migration. We speculate that the C-terminus
domain of HPA may mediate AGEs-induced macrophage
migration via AKT signaling pathway.
Subsequently, we detected the role of PI3K/AKT sig-
naling pathway in AGEs-induced macrophage migration
via HPA. AKT is a target of PI3K activation and its
phosphorylation is prevented by PI3K/AKT inhibitors.
Although AKT phosphorylation is increased by external
HPA in a short time, the AKT phosphorylation induced
by changes of HPA protein after AGEs treatment may
need longer time. So we chose to determine the levels of
AKT at 24 h culture. The results show that the levels of
AKT phosphorylation was increased at 24 h in macro-
phage cultured with AGEs. Pretreatment with an anti-
body recognizing the C-terminus domain of HPA
protein inhibited AKT phosphorylation significantly
(Figure 4). The results suggest that AGEs could activatePI3K/AKT signaling pathway via C-terminus domain of
HPA protein. Furthermore, we observed that AGEs-
induced cell migration was attenuated by using LY294002,
a PI3K/AKT inhibitor, in macrophages (Figure 2). These
data indicate that the AGEs-induced macrophage migra-
tion is partially mediated by the activation of PI3K/AKT
signaling pathway in HPA-dependent manner. HPA-PI3K/
AKT signal pathway may be important in macrophage mi-
gration induced by AGEs.
Recently, it was reported that AGEs could induce HPA
expression through receptor for advanced glycation end
products (RAGE) in human microvascular endothelial
cells [19]. Substantial evidence has demonstrated that
RAGE plays a central role in the etiology of diabetes
complications and inflammation [38-40]. RAGE ligand,
such as HMGB-1, could stimulate phosphorylation of
AKT and cell proliferation/migration through RAGE/
PI3K/AKT signal transduction pathway [41,42]. Here we
assess the role of RAGE on HPA expression and AKT
pathway which associated with macrophage migration.
We observed that treatment with AGEs for 24 h cul-
ture resulted into significant increase of HPA mRNA,
HPA latent form (65 kDa) and enzyme form (50 kDa)
compared with untreated cells. 50 kDa enzyme form is
more strongly induced than 65 kDa latent form. All the
changes could be attenuated by pretreatment with anti-
RAGE antibody (Figure 3A and 3C). These results show
that increased expression of HPA mRNA and protein
are associated with AGEs stimulation via RAGE and
HPA protein expression may partly dependent of post-
transcriptional regulation in macrophages.
Furthermore, ELISA analysis was employed to determine
the levels of HPA in supernatant. We discovered that pre-
treatment with anti-RAGE antibody inhibited the increased
secretion of HPA in AGEs-stimulated macrophages signifi-
cantly (Figure 3B). The result from ELISA suggests that
AGEs could induce HPA protein secretion via RAGE as
well as the results from Western blot. These data provide
the first evidence for AGEs-induced macrophage HPA
mRNA, protein expression and secretion in a RAGE-
dependent manner. RAGE-HPA pathway may play a key
role in AGEs-induce macrophage migration.
To analyze the relation between RAGE, AKT phospho-
rylation and migration to further demonstrate RAGE-
HPA-PI3K/AKT pathway, an antibody against RAGE is
used to block the effect of RAGE in AGEs-induced
macrophages. The results show that pretreatment of the
cells with the blocking antibody to RAGE suppressed
AGEs-induced AKT phosphorylation (Figure 4) and cell
migration significantly in macrophages (Figure 2). The re-
sult suggests that RAGE could mediate AGEs-induced
macrophage migration via AKT pathway and agrees to
RAGE-HPA-PI3K/AKT pathway associated with AGEs-
stimulated macrophage migration.
Qin et al. Cardiovascular Diabetology 2013, 12:37 Page 8 of 9
http://www.cardiab.com/content/12/1/37Conclusions
Our results show for the first time that AGEs-induced
macrophage migration may be mediated by RAGE-HPA-
PI3K/AKT signal pathway. It supports the notion that
HPA could mediate macrophage migration involving in
RAGE-HPA-PI3K/AKT pathway independent of enzym-
atic activity, providing new insights into the role of HPA
in AGEs-induced macrophage migration associated with
vascular complication of diabetes. The mechanism such as
regulation of HPA expression and AKT phosphorylation
mediated by HPA might be required for further studies.
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